Dacarbazine (DTIC)
Sponsors
Vical, M.D. Anderson Cancer Center, GlaxoSmithKline, OrienGene Biotechnology Ltd., University of Erlangen-Nürnberg Medical School
Conditions
CancerImmunotherapyLymphomaMelanoma (Skin)Melanoma Stage IMelanoma Stage IIMelanoma Stage IIIMetastatic Melanoma
Phase 2
Rituximab and ABVD for Hodgkin's Patients
CompletedNCT00504504
Start: 2001-03-31End: 2012-03-31Updated: 2013-07-09
A Clinical Study to Evaluate the Safety and Efficacy of OrienX010 in Unresectable Malignant Melanoma Patients
NCT04200040
Start: 2017-08-27End: 2022-12-27Target: 165Updated: 2020-02-27
Preconditioning of Tumor, Tumor Microenvironment and the Immune System to Immunotherapy
CompletedNCT04225390
Start: 2020-01-13End: 2026-01-15Updated: 2026-02-10
Adjuvant Therapy of Skin Melanoma With Alpha Interferon and Naderin
CompletedNCT07671495
Start: 2014-01-01End: 2018-12-01Updated: 2026-06-30
Phase 3
A Phase 3 Pivotal Trial Comparing Allovectin-7® Alone vs Chemotherapy Alone in Patients With Stage 3 or Stage 4 Melanoma
CompletedNCT00395070
Start: 2006-10-31End: 2013-07-31Updated: 2013-09-13
A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma
CompletedNCT01227889
Start: 2010-12-23End: 2016-09-16Updated: 2017-10-04